-
Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer. J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-08 Jacobi B. Hines MD, Robert B. Cameron MD PhD, Alessandra Esposito PhD, Leeseul Kim MD, Luca Porcu PhD, Antonio Nuccio MD, Giuseppe Viscardi MD PhD, Roberto Ferrara MD, Giulia Veronesi MD, Patrick M. Forde MD, Janis Taube MD, Everett Vokes MD, Christine M. Bestvina MD, James M. Dolezal MD PhD, Matteo Sacco, Marta Monteforte MD, Tina Cascone MD PhD, Marina C. Garassino MD, Valter Torri MD
Controversy remains as to whether pathologic complete response (pCR) and major pathologic response (MPR) represent surrogate endpoints for event free survival (EFS) and overall survival (OS) in neoadjuvant trials for resectable non-small cell lung cancer (NSCLC). A search of PubMed and archives of international conference abstracts was performed from June 2017 through October 31, 2023. Studies incorporating
-
Response to Letter to the Editor J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 Mi Hee Cho MD PhD, Jong Ho Cho MD PhD, Dong Wook Shin MD DrPH MBA
-
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 Lanyi Nora Chen MD, Alexandria T.M. Lee MD, Misako Nagasaka MD PhD, Sai-Hong Ignatius Ou MD PhD
-
MUC1-C: The Occam Razor of Osimertinib Resistance? J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 Anirudh Yalamanchali MD MS, Khaled A. Hassan MD MS
-
How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer? J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 Bo-Guen Kim MD PhD, Sanghyuk Yoon MPH, Sun Yeop Lee MS, Jang Won Sohn MD PhD, Dong Won Park MD PhD
-
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 Sun Min Lim MD PhD, Jii Bum Lee MD, Byoung Chul Cho MD PhD
-
Response to Letter to the Editor J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 N, o, b, u, t, e, r, u, , K, u, b, o, , M, D, , P, h, D
-
Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 K, e, v, i, n, , t, e, n, , H, a, a, f, , P, h, D
-
Lung Cancer in Switzerland J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 Raphael Sven Werner MD MSc, Alessandra Curioni-Fontecedro MD, Laetitia A. Mauti MD, Alfredo Addeo MD, Solange Peters MD PhD, Thomas Frauenfelder MD, Milo A. Puhan MD PhD, Martina Haberecker MD, Lukas Bubendorf MD, Tobias Finazzi MD, Matthias Guckenberger MD, Stefano Cafarotti MD, Thomas Geiser MD, Isabelle Opitz MD, SAKK
-
Anti–Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 Floris Dammeijer MD PhD, Daphne W. Dumoulin MD, Joachim G.J.V. Aerts MD PhD
-
Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on Pie Slices J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 Massimiliano Cani MD, Silvia Novello PhD, Paolo Bironzo PhD
-
Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 Chen-Pi Li MS, Ru-Yin Tsai PhD, Hui-Chin Chang MLS, Shuo-Yan Gau
-
Invasive Size in Lung Adenocarcinoma—Reproducible Criteria, More Accurate Staging J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-05 A, l, a, i, n, , C, ., , B, o, r, c, z, u, k, , M, D
-
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-03-04 Ramón Rami-Porta MD, Katherine K. Nishimura PhD MPH, Dorothy J. Giroux MS, Frank Detterbeck MD, Giuseppe Cardillo FRCS FETCS, John G. Edwards PhD FRCS(C/Th), Kwun M. Fong MD MBBS FRACP, Meredith Giuliani MBBS, James Huang MD, Kemp H. Kernstine Sr. MD PhD, Edith M. Marom MD, Andrew G. Nicholson DM FRCPath, Paul E. Van Schil MD, William D. Travis MD, Ming S. Tsao MD, Shun-Ichi Watanabe MD, Valerie W
The tumor, node and metastasis (TNM) classification of lung cancer is periodically revised. The International Association for the Study of Lung Cancer collected and analyzed a new database to inform the forthcoming 9 edition of the TNM classification. The results are herewith presented. After exclusions, 76,518 patients from a total of 124,581 registered patients, were available for analyses: 58,193
-
Passive Smoking–Induced Mutagenesis as a Promoter of Lung Carcinogenesis J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-19 Akifumi Mochizuki MD, Kouya Shiraishi PhD, Takayuki Honda MD PhD, Ryoko Inaba Higashiyama MD, Kuniko Sunami MD PhD, Maiko Matsuda MS, Yoko Shimada MS, Yasunari Miyazaki MD PhD, Yukihiro Yoshida MD PhD, Shun-Ichi Watanabe MD PhD, Yasushi Yatabe MD PhD, Ryuji Hamamoto PhD, Takashi Kohno PhD
The International Agency for Research on Cancer has classified passive smoking (PS) or secondhand smoke exposure as a group 1 carcinogen linked to lung cancer. However, in contrast to active smoking, the mutagenic properties of PS remain unclear. A consecutive cohort of 564 lung adenocarcinoma samples from female never-smokers, who provided detailed information about their exposure to PS during adolescence
-
Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-09 Liam James Dwyer, Nimit Singhal, Bing Yu, Steven Kao
Adjuvant osimertinib represents a recent paradigm shift in the management of resected EGFR-mutated lung cancer. The optimal subsequent treatment of patients who relapse after completion of 3 years of adjuvant osimertinib is unknown. Here, we report two cases of complete response to osimertinib rechallenge after relapse from previous adjuvant osimertinib use, and a serial molecular panel exhibiting
-
-
A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Tadashi Nishimura
-
SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep? J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Taofeek K. Owonikoko
-
Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Xiuning Le
-
The Joint Problem of Rheumatoid Arthritis and Lung Cancer J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Bonnie L. Bermas, David E. Gerber
-
Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically? J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Jih-Hsiang Lee
-
Response to Letter to the Editor J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Mi Hee Cho, Jong Ho Cho, Dong Wook Shin
-
-
-
A Response to the Letter to the Editor: “A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment” J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Masahiro Torasawa, Hidehito Horinouchi
-
-
-
Tobacco News Update - From the IASLC Tobacco Control Committee J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05
-
An Error in Modeling and the Selection of Independent Radiomics Variables Need Caution J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Cheng Yuan, Runqiu Huang, Yang Wang
-
Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Nobuyuki Horita, Kaoru Takase-Minegishi
-
In Response J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Mi Hee Cho, Jong Ho Cho, Dong Wook Shin
-
-
Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-05 Hui-Chin Chang, Shuo-Yan Gau
-
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-04 Kwun M. Fong, Adam Rosenthal, Dorothy J. Giroux, Katherine K. Nishimura, Jeremy Erasmus, Yolande Lievens, Mirella Marino, Edith M. Marom, Paul Martin Putora, Navneet Singh, Francisco Suárez, Ramon Rami-Porta, Frank Detterbeck, Wilfried EE. Eberhardt, Hisao Asamura
This study analyzed all metastatic categories of the current tumor, node, and metastasis (TNM) classification of non-small cell lung cancer to propose modifications of the M component in the next edition (9) of the classification. A database of 124,581 patients diagnosed between 2011 and 2019 was established; of these, 14,937 with NSCLC in stage IVA-IVB were available for this analysis. Overall survival
-
Global Burden of Lung Cancer Attributable to Household Fine Particulate Matter Pollution in 204 Countries and Territories, 1990 to 2019 J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-02 Run-Xuan Zhou, Hong-Jin Liao, Jun-Jie Hu, Hua Xiong, Xiu-Yu Cai, Da-Wei Ye
Household Particulate matter (PM) air pollution is significantly associated with lung cancer. Nevertheless, the global burden of lung cancer attributable to household PM2.5 is still uncertain. In this study, data from the Global Burden and Disease Study (GBD) 2019 are used to thoroughly assess the burden of lung cancer associated with household PM2.5. The number of deaths and disability-adjusted life
-
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-02-01 Andrea S. Wolf MD MPH, Megan Eisele MS, Dorothy J. Giroux MS, Ritu Gill MD, Anna K. Nowak M.B.B.S. FRACP PhD, Andrea Bille MD, David Rice MD, Robert T. Ripley MD, Isabelle Opitz MD, Francoise Galateau-Salle MD, Seiki Hasegawa MD, Hedy L. Kindler MD, Harvey I. Pass MD, Valerie W. Rusch MD, Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee
-
Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/Ⅱ Study J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-29 Yuankai Shi, Xingsheng Hu, Xingya Li, Caifeng Gong, Ke Wang, Yongsheng Li, Shucai Zhang, Yongzhong Luo, Pingli Wang, Liyan Jiang, Xiangjiao Meng, Xiaorong Dong, Huijuan Wang, Runxiang Yang, Qi Mei, Baogang Liu, Limin Yang, Yinghui Sun
Introduction Treatment options for second-generation (2nd-gen) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) resistant patients are limited. We evaluated the safety, pharmacokinetics, and efficacy of ficonalkib (SY-3505), a third-generation (3rd-gen) ALK TKI. Methods This first-in-human, phase I/Ⅱ study (Chinese Clinical Trial Registry identifier: ChiCTR1900025619; ClinicalTrials
-
Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE) J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-25 Yuankai Shi, Jianhua Chen, Runxiang Yang, Hongbo Wu, Zhehai Wang, Weihua Yang, Jiuwei Cui, Yiping Zhang, Chunling Liu, Ying Cheng, Yunpeng Liu, Jinlu Shan, Donglin Wang, Lei Yang, Changlu Hu, Jian Zhao, Ranhua Cao, Bangxian Tan, Ke Xu, Meimei Si, Lin Wang
Background Iruplinalkib (WX-0593) is a new-generation, potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) and has shown systemic and central nervous system (CNS) efficacy in ALK-positive non-small-cell lung cancer (NSCLC). We compared the efficacy and safety of iruplinalkib with crizotinib in ALK TKI-naïve, locally advanced or metastatic ALK-positive NSCLC patients. Methods In
-
-
Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-24 Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances Shepherd, Chao Xu, David Kaldas, Jhanelle E. Gray, Thomas J. Dilling, Joel W. Neal, Heather A. Wakelee, Yufei Liu, Steven H. Lin, Tariq Abuali, Arya Amini, Yunan Nie, Tejas Patil, Anastasiya Lobachov, Jair Bar, Bailey Fitzgerald, Sarah B. Goldberg
-
Lung cancer oncogene-directed therapy, fertility and pregnancy J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-06 Emily Simons, D. Ross Camidge
Introduction Alterations in the highly-actionable lung cancer oncogenes, EGFR, ALK and ROS1, occur across the age spectrum. Pregnancy and plans for motherhood consequently overlap with diagnoses of advanced oncogene-driven non-small cell lung cancer (NSCLC.) Guidelines for cytotoxic agents and pregnancy are well-established. However, accessible data on targeted lung cancer therapy during pregnancy
-
-
-
Tale of Two Cs: Inter-Relationship Between Cardiovascular and Lung Cancer J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-05 Heya Batah, Zoha Majeed, Rohit Moudgil
Abstract not available
-
-
-
In This Issue/News in Brief J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-05
Abstract not available
-
Tobacco News Update - From the IASLC Tobacco Control Committee J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-05
Abstract not available
-
Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-05 Surbhi Singhal, David Gandara, Jonathan W. Riess
Abstract not available
-
Unraveling Pseudo Kidney Injury: The Significance of Understanding Our “MATE” in Molecular-Targeted Therapies J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-05 Junko Tanizaki, Hidetoshi Hayashi
Abstract not available
-
Comment on “Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial” J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-05 Shaorong Yu, Jifeng Feng
Abstract not available
-
Response to Letter to the Editor From Shaorong Yu and Jifeng Feng J. Thorac. Oncol. (IF 20.4) Pub Date : 2024-01-05 Marina C. Garassino, Corinne Faivre-Finn
Abstract not available
-
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non‒Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial J. Thorac. Oncol. (IF 20.4) Pub Date : 2023-12-29 James Chih-Hsin Yang, Baohui Han, Emmanuel De La Mora Jiménez, Jong-Seok Lee, Piotr Koralewski, Nuri Karadurmus, Shunichi Sugawara, Lorenzo Livi, Naveen S. Basappa, Xavier Quantin, Julia Dudnik, Diego Moran Ortiz, Tarek Mekhail, Chinyere E. Okpara, Corina Dutcus, Zachary Zimmer, Ayman Samkari, Niyati Bhagwati, Tibor Csőszi
Introduction Lenvatinib plus pembrolizumab demonstrated antitumor activity and acceptable safety in previously treated metastatic NSCLC. We evaluated first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in metastatic NSCLC in the LEAP-007 study (NCT03829332/NCT04676412). Methods Patients with previously untreated stage IV NSCLC with programmed cell death ligand 1 (PD-L1) tumor
-
Initial chemotherapy for locally advanced and metastatic NUT carcinoma J. Thorac. Oncol. (IF 20.4) Pub Date : 2023-12-27 Jia Luo, Michelle Sanchez, Elinton Lee, Hans Hertzler, Nhi Luong, Emanuele Mazzola, Bryanna Finstein, Rubii Tamen, Gifty Brisbane, Tom Nguyen, Paul K. Paik, Jamie E. Chaft, Michael L. Cheng, Hassan Khalil, Sarina A. Piha-Paul, Lynette M. Sholl, Mizuki Nishino, Pasi A. Jänne, Steven G. DuBois, Glenn J. Hanna, Christopher A. French
-
Comparative Effectiveness of Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma Patients Undergoing Curative-Intent Concurrent Chemoradiotherapy J. Thorac. Oncol. (IF 20.4) Pub Date : 2023-12-26 Chia-Lun Chang, Kuan-Chou Lin, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu
Background This study compared outcomes in inoperable esophageal squamous cell carcinoma (ESCC) patients undergoing curative-intent concurrent chemoradiotherapy (CCRT) with intensity-modulated radiotherapy (IMRT) versus intensity-modulated proton therapy (IMPT). Methods The study encompassed a retrospective cohort analysis of inoperable ESCC patients who underwent curative-intent CCRT from January
-
Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer J. Thorac. Oncol. (IF 20.4) Pub Date : 2023-12-26 Igor Odintsov, Maisam Makarem, Mizuki Nishino, Sara Emily Bachert, Tom Zhang, Jaclyn LoPiccolo, Cloud P. Paweletz, Prafulla C. Gokhale, Elena Ivanova, Aisha Saldanha, Charles M. Rudin, William W. Lockwood, Marc Ladanyi, Romel Somwar, Pasi A. Jänne, Lynette M. Sholl
Background ERBB2 amplification in lung cancer remains poorly characterized. HER2 (encoded by ERBB2) is a transmembrane tyrosine kinase capable of ligand-independent dimerization and signaling when overexpressed, and a common cause of HER2 overexpression is ERBB2 amplification. Here we evaluated the clinicopathologic and genomic characteristics of ERBB2-amplified NSCLC and explored a HER2 ADC therapeutic
-
Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM) J. Thorac. Oncol. (IF 20.4) Pub Date : 2023-12-13 Philip Bischoff, Martin Reck, Tobias Overbeck, Petros Christopoulos, Achim Rittmeyer, Heike Lüders, Jens Kollmeier, Jonas Kulhavy, Marcel Kemper, Niels Reinmuth, Julia Röper, Melanie Janning, Linna Sommer, Lukas Aguinarte, Myriam Koch, Marcel Wiesweg, Claas Wesseler, Cornelius F. Waller, Diego Kauffmann-Guerrero, Albrecht Stenzinger, Nikolaj Frost
-
Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the ITMIG/ESTS Database J. Thorac. Oncol. (IF 20.4) Pub Date : 2023-12-08 Andreas Rimner, Usman Ahmad, Stephanie M. Lobaugh, Zhigang Zhang, Annemarie F. Shepherd, James Huang, Alberto Antonicelli, Nicolas Girard, Bernhard Moser, Pierluigi Filosso, Marco Lucchi, Edith M. Marom, Anja Roden, Frank Detterbeck, Enrico Ruffini, Charles B. Simone
-
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer J. Thorac. Oncol. (IF 20.4) Pub Date : 2023-12-07 Paul E. Van Schil, Hisao Asamura, Katherine K. Nishimura, Ramon Rami-Porta, Young Tae Kim, Pietro Bertoglio, Ayten K. Cangir, Jessica Donington, Wentao Fang, Dorothy J. Giroux D, Yolande Lievens, Hui Liu, Gustavo Lyons, Shuji Sakai, William D. Travis, Paula Ugalde, Chi-Fu Jeffrey Yang, Masaya Yotsukura, Frank Detterbeck